Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 38 of 62 for:    Baricitinib

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis (BREEZE-AD7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03733301
Recruitment Status : Completed
First Posted : November 7, 2018
Last Update Posted : September 23, 2019
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Baricitinib Drug: Topical corticosteroid Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 329 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7
Actual Study Start Date : November 16, 2018
Actual Primary Completion Date : July 29, 2019
Actual Study Completion Date : August 22, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema Steroids

Arm Intervention/treatment
Experimental: Baricitinib High Dose
Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
Drug: Baricitinib
Administered orally.
Other Name: LY3009104

Drug: Topical corticosteroid
Administered as standard-of-care.

Drug: Placebo
Administered orally.

Experimental: Baricitinib Low Dose
Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
Drug: Baricitinib
Administered orally.
Other Name: LY3009104

Drug: Topical corticosteroid
Administered as standard-of-care.

Drug: Placebo
Administered orally.

Placebo Comparator: Placebo
Placebo administered orally in combination with topical corticosteroids.
Drug: Topical corticosteroid
Administered as standard-of-care.

Drug: Placebo
Administered orally.




Primary Outcome Measures :
  1. Proportion of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 with a ≥ 2 Point Improvement [ Time Frame: 16 Weeks ]
    Proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement


Secondary Outcome Measures :
  1. Proportion of Participants Achieving Eczema Area and Severity Index 75 (EASI75) [ Time Frame: 16 Weeks ]
    Proportion of participants achieving EASI75

  2. Proportion of Participants Achieving EASI90 [ Time Frame: 16 Weeks ]
    Proportion of participants achieving EASI90

  3. Percent Change from Baseline on EASI Score [ Time Frame: Baseline, 16 Weeks ]
    Percent change from baseline on EASI Score

  4. Proportion of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75) [ Time Frame: 16 Weeks ]
    Proportion of participants achieving SCORAD75

  5. Proportion of Participants Achieving a 4-Point Improvement on the Itch Numeric Rating Scale (NRS) [ Time Frame: 16 Weeks ]
    Proportion of participants achieving a 4-Point improvement on the Itch NRS

  6. Change from Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS) [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the score of item 2 of the ADSS

  7. Change from Baseline in Skin Pain NRS [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in skin pain NRS

  8. Proportion of Participants Achieving EASI50 [ Time Frame: 16 Weeks ]
    Proportion of participants achieving EASI50

  9. Proportion of Participants Achieving IGA of 0 [ Time Frame: 16 Weeks ]
    Proportion of participants achieving IGA of 0

  10. Change from Baseline in SCORAD [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in SCORAD

  11. Proportion of Participants Achieving SCORAD90 [ Time Frame: 16 Weeks ]
    Proportion of participants achieving SCORAD90

  12. Change from Baseline in Body Surface Area (BSA) Affected [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in BSA affected

  13. Proportion of Participants Developing Skin Infections Requiring Antibiotic Treatment [ Time Frame: 16 Weeks ]
    Proportion of participants developing skin infections requiring antibiotic treatment

  14. Mean Gram Quantity of TCS Use (Tube Weights) [ Time Frame: 16 Weeks ]
    Mean gram quantity of TCS use (tube weights)

  15. Percent Change from Baseline in Itch NRS [ Time Frame: Baseline, 16 Weeks ]
    Percent change from baseline in Itch NRS

  16. Change from Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM) [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the total score of the POEM

  17. Change from Baseline in the Patient Global Impression of Severity—Atopic Dermatitis (PGI-S-AD) Score [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline in the PGI-S-AD score

  18. Change from Baseline on the Hospital Anxiety Depression Scale (HADS) [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline on the HADS

  19. Change from Baseline on the Dermatology Life Quality Index (DLQI) [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline on the DLQI

  20. Change from Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire [ Time Frame: Baseline, 16 Weeks ]
    Change from baseline on the WPAI-AD questionnaire

  21. Change from Baseline on the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) [ Time Frame: Baseline, 16 Weeks ]
    Change from Baseline on the EQ-5D-5L

  22. Mean Number of Days without Use of Background TCS [ Time Frame: Baseline through 16 Weeks ]
    Mean number of days without use of background TCS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have been diagnosed with moderate to severe atopic dermatitis for at least 12 months.
  • Have had inadequate response to existing topical (applied to the skin) medications within 6 months preceding screening.
  • Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).
  • Agree to use emollients daily.

Exclusion Criteria:

  • Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
  • A history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
  • Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
  • Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
  • Have been treated with the following therapies:

    • Monoclonal antibody for less than 5 half-lives prior to randomization.
    • Received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks prior to randomization.
    • Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
    • Have had an intra-articular corticosteroid injection within 6 weeks prior to planned randomization.
  • Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
  • Have had major surgery within the past eight weeks or are planning major surgery during the study.
  • Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
  • Have a history of recurrent (≥2) VTE or are considered at high risk of VTE as deemed by the investigator.
  • Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
  • Have specific laboratory abnormalities.
  • Have received certain treatments that are contraindicated.
  • Pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03733301


  Show 68 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Incyte Corporation
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Additional Information:
Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT03733301     History of Changes
Other Study ID Numbers: 17100
I4V-MC-JAIY ( Other Identifier: Eli Lilly and Company )
2018-001726-26 ( EudraCT Number )
First Posted: November 7, 2018    Key Record Dates
Last Update Posted: September 23, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
URL: http://www.clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eli Lilly and Company:
eczema
atopic eczema
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases